Sumary of Remdesivir: don’t use drug Trump took for Covid-19, WHO says:
- The WHO issued what it calls a “living guideline”, which can be updated as evidence comes in, largely as a result of a Solidarity trial it led in several countries..
- Solidarity allocated patients randomly to several drugs including remdesivir and found that those who took it were no more likely to survive severe Covid than those who did not..
- The guideline, published in the British Medical Journal, concluded that “most patients would not prefer intravenous treatment with remdesivir given the low certainty evidence..
- Any beneficial effects of remdesivir, if they do exist, are likely to be small and the possibility of important harm remains.”.
- Solidarity, which analysed the outcomes from more than 7,000 adults admitted to hospital with Covid-19 in four randomised controlled trials, had found no evidence of a meaningful benefit, he said..
- “Given this lack of evidence of any benefit on mortality, the risk of ending up on a ventilator or the time to clinical improvement, the World Health Organization have reasonably recommended against the use of remdesivir in patients hospitalised with Covid-19, whatever their disease severity…